Xenon Pharmaceuticals (NASDAQ:XENE) Announces Quarterly Earnings Results, Hits Estimates

Xenon Pharmaceuticals (NASDAQ:XENE) released its quarterly earnings results on Thursday. The biopharmaceutical company reported ($1.17) earnings per share for the quarter, hitting analysts’ consensus estimates of ($1.17), Zacks reports. During the same period in the previous year, the firm posted ($0.83) earnings per share.

Here are the key takeaways from Xenon Pharmaceuticals’ conference call:

• Xenon’s Phase III X-TOLE2 for azetukalner (AZK) exceeded expectations with strong efficacy and tolerability, and the company plans an NDA submission in Q3 2026 with an anticipated U.S. launch in late 2027/early 2028 (standard FDA review + DEA scheduling).
• Long-term open-label data are compelling — ≥48-month patients showed a 91% median reduction in monthly focal seizures and ~40% were seizure-free for ≥12 months, supporting AZK’s potential differentiation and durable benefit.
• Xenon is expanding AZK’s opportunity beyond focal epilepsy — EXACT (primary generalized tonic‑clonic seizures) is enrolling and three Phase III depression studies (X‑NOVA 2 readout expected H1 2027) could materially broaden the addressable market if successful.
• Early-stage pain programs XEN1701 (NaV1.7) and XEN1120 (KV7) are completing first‑in‑human studies this year with plans to advance to Phase II acute pain POC trials, but these are early-stage and carry typical development risk.
• Financially strong after a $747.5M offering, Xenon ended Q1 with about $1.3 billion in cash and equivalents, which management says funds operations into 2029 and supports launch and pipeline advancement.

Xenon Pharmaceuticals Price Performance

Shares of XENE stock opened at $56.00 on Friday. The firm has a market cap of $5.41 billion, a P/E ratio of -12.84 and a beta of 0.65. Xenon Pharmaceuticals has a 1-year low of $28.19 and a 1-year high of $63.95. The firm has a fifty day moving average of $54.64 and a two-hundred day moving average of $46.62.

Wall Street Analyst Weigh In

A number of equities research analysts recently weighed in on XENE shares. Stifel Nicolaus set a $66.00 price target on shares of Xenon Pharmaceuticals in a report on Tuesday, February 10th. Deutsche Bank Aktiengesellschaft raised their target price on Xenon Pharmaceuticals from $56.00 to $90.00 and gave the company a “buy” rating in a research note on Tuesday, March 10th. Wells Fargo & Company boosted their price target on Xenon Pharmaceuticals from $49.00 to $68.00 and gave the stock an “overweight” rating in a research note on Tuesday, March 10th. Robert W. Baird increased their price target on Xenon Pharmaceuticals from $63.00 to $97.00 and gave the company an “outperform” rating in a report on Monday, March 9th. Finally, Guggenheim restated a “buy” rating and set a $90.00 price objective on shares of Xenon Pharmaceuticals in a research note on Monday, March 9th. Two analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, Xenon Pharmaceuticals presently has a consensus rating of “Buy” and a consensus price target of $73.13.

Insider Activity

In related news, CEO Ian Mortimer sold 7,308 shares of the business’s stock in a transaction dated Friday, March 13th. The stock was sold at an average price of $55.23, for a total value of $403,620.84. Following the completion of the sale, the chief executive officer directly owned 19,923 shares of the company’s stock, valued at $1,100,347.29. The trade was a 26.84% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Andrea Difabio sold 1,342 shares of the stock in a transaction that occurred on Friday, March 13th. The stock was sold at an average price of $55.23, for a total value of $74,118.66. Following the transaction, the insider directly owned 7,301 shares in the company, valued at approximately $403,234.23. This represents a 15.53% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last 90 days, insiders have sold 296,707 shares of company stock worth $17,845,365. 4.07% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Xenon Pharmaceuticals

Several institutional investors and hedge funds have recently made changes to their positions in the company. Holocene Advisors LP bought a new position in Xenon Pharmaceuticals during the second quarter worth $56,637,000. Wellington Management Group LLP raised its holdings in shares of Xenon Pharmaceuticals by 66.0% during the third quarter. Wellington Management Group LLP now owns 3,609,857 shares of the biopharmaceutical company’s stock worth $144,936,000 after purchasing an additional 1,435,096 shares during the period. Price T Rowe Associates Inc. MD raised its holdings in shares of Xenon Pharmaceuticals by 1,968.3% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 862,300 shares of the biopharmaceutical company’s stock worth $38,650,000 after purchasing an additional 820,608 shares during the period. Vestal Point Capital LP lifted its position in shares of Xenon Pharmaceuticals by 53.8% in the 2nd quarter. Vestal Point Capital LP now owns 2,000,000 shares of the biopharmaceutical company’s stock worth $62,600,000 after buying an additional 700,000 shares during the last quarter. Finally, Commodore Capital LP boosted its holdings in shares of Xenon Pharmaceuticals by 30.1% in the 2nd quarter. Commodore Capital LP now owns 3,025,000 shares of the biopharmaceutical company’s stock valued at $94,682,000 after buying an additional 700,000 shares during the period. 95.45% of the stock is owned by institutional investors and hedge funds.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals Inc is a clinical‐stage biopharmaceutical company dedicated to discovering and developing novel, small‐molecule drugs targeting ion channels in the central and peripheral nervous system. The company’s research focus centers on neurological and pain disorders—including epilepsy, migraine, and neuropathic pain—by modulating key ion‐channel proteins to restore normal neuronal function. Xenon’s scientific platform draws upon advances in ion‐channel biology and structure‐based drug design to identify and optimize therapeutic candidates with the potential for improved safety and efficacy profiles compared with existing treatments.

The company’s pipeline comprises multiple preclinical and clinical programs.